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Immune thrombocytopenic purpura (ITP) is an acquired disease in
which autoantibodies to platelets cause their sequestration and
destruction by mononuclear macrophages, principally in the
spleen. If increased production of platelets by megakaryocytes
does not compensate for platelet destruction, the number of
circulating platelets decreases (thrombocytopenia), resulting in a
characteristic bleeding tendency (purpura). While most children
with the disease experience a relatively short and benign clinical
course, ITP in adults often lasts more than 6 months (chronic ITP)
and is resistant to conventional treatment (corticosteroids,
intravenous immune globulin, or splenectomy). The goal of
medical management is to increase the platelet count to a safe level,
without the risks of bacterial infections associated with
splenectomy or toxicity from prolonged corticosteroid therapy.
Splenectomy increases platelet counts in hours to days in most
patients with acute ITP, but nearly 50 percent experience
recurrent thrombocytopenia by 5 years postsplenectomy.
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Introduction
Immune thrombocytopenic purpura (ITP,
idiopathic or autoimmune thrombocytopenic purpura)
is an acquired bleeding disorder of children and adults
that presents with thrombocytopenia as the only
significant abnormal laboratory finding. There is
neither a specific clinical nor a laboratory finding that
reliably establishes a diagnosis of ITP. A diagnosis of
ITP is established by excluding other potential causes
of thrombocytopenia.
Classification
ITP is a heterogeneous disease with a wide range of
clinical and laboratory presentations. Typically,patients
are classified according to age at the time of diagnosis
(ITP in children versus adults),but no one classification
system is capable of segregating patients with this
highly variable disease into categories without a
significant number of exceptions. The goal of
classifying patients is to be able to match a newly
diagnosed patient with a group of other patients with
similar findings for purposes of selecting an
appropriate treatment and providing prognostic
information.
Primary versus secondary immune
thrombocytopenia
Conventionally, thrombocytopenias are divided
into three major categories: those resulting from (1)
abnormally decreased platelet production (e.g.,aplastic
anemia), (2) platelet sequestration (e.g.,
hypersplenism), or (3) abnormally increased platelet
destruction (e.g., immune destruction). Immune
(antibody-mediated) thrombocytopenia may occur as a
complication of another disease (secondary
thrombocytopenia) (e.g., HIV/AIDS, systemic lupus
erythematosis, or a primary immunodeficiency
syndrome) or as the only abnormal finding (primary
immune thrombocytopenia). In the following review,
“ITP” is intended to refer to primary immune
thrombocytopenia.
ITP in children versus in adults
Typically, children with ITP present with an acute
onset of petechiae and diffuse bruising approximately
4 to 8 weeks after a viral illness. As many as 85 percent
of affected children experience an uneventful course
and spontaneous remission within 6 months.1 In 2003,
the International Childhood ITP Study Group reported
the results of a prospective study of 2540 infants and
children with newly diagnosed ITP, providing
voluminous data on the clinical spectrum of childhood
ITP.2 In this study, the incidence of intracranial
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children,was only 0.17% during the first 6 months after
diagnosis. In contrast to ITP in children, ITP in adults
typically presents with an insidious onset; affects a
preponderance of females, as seen in other auto-
immune diseases in adults; and progresses to chronic
ITP (persistent thrombocytopenia or a requirement for
treatment 6 months after onset). This traditional profile
of ITP in adults has been challenged by the results of a
prospective study reported in 2003 for a population
cohort of 245 adults with ITP in the UK.3 In this study,
there were 134 females/111 males (1.2:1.0) and the
majority of patients (63.3%) achieved remission
(platelet count > 100,000/µL) and an additional 24
percent achieved a partial remission.
Pathophysiology
Harrington’s “thrombocytopenic factor”
While splenectomy has been recognized as an
effective treatment for patients with ITP since it was
first described in 1913,4 the modern concept of the
pathophysiology of ITP began in 1951 when
Harrington et al.5 reported “a thrombocytopenic
factor” in the blood of patients with ITP. Harrington
infused himself and seven other nonthrombocytopenic
subjects with whole blood or plasma from patients
with “idiopathic” thrombocytopenic purpura and
observed a rapid decrease in most recipients’ platelet
counts. One patient’s plasma was fractioned by Cohn’s
method and the thrombocytopenic effect was localized
to the globulin fraction. This observation might have
justified changing the name from “idiopathic” to
“immune” thrombocytopenic purpura more than 50
years ago, but the designation “idiopathic” persists in
common usage, even today.
Platelet autoantibodies
Autoantibodies that react with platelet membrane
glycoproteins have been demonstrated in as many as
80 percent of patients with ITP.6 These antibodies
react with glycoproteins IIb/IIIa (αIIbβ3 integrin or
CD41/CD61), GPIb/IX, and others. As a consequence,
autoantibody-coated platelets are phagocytized in the
reticuloendothelial system (RES) via Fcγ receptors on
mononuclear macrophages. Technically, the name
“reticuloendothelial system” is a misnomer, with
recognition that RES mononuclear phagocytes are
neither reticular nor endothelial cells.7 However, the
traditional concept that the spleen, liver, and bone
marrow are functional sites for RES phagocytic activity
is useful and is preserved in this review. Intuitively, one
might expect that the severity of bleeding in patients
with ITP would correlate with the presence of one or
more of these antibodies, since their glycoprotein
targets are integral to normal platelet function and
hemostasis. However, current laboratory assays for
platelet antibodies do not demonstrate a convincing
correlation between specific glycoprotein targets and
disease severity.6 Neither research-level nor
commercially marketed assays for detecting platelet
antibodies have sufficient specificity to be useful as
diagnostic assays for ITP in clinical practice.8 An
evaluation of the performance of Capture-P (Immucor,
Inc., Norcross, GA), a commercially marketed kit for
indirect platelet antibody tests, concluded that the
method was not useful for establishing or excluding
the diagnosis of ITP.8 This finding is consistent with
the American Society of Hematology’s practice
guideline, which concluded that current tests for
platelet antibodies are neither necessary nor
appropriate in the evaluation of ITP in children or
adults.8 Recently, serologic reactivity of ITP
autoantibodies has been further localized to epitopes
on αIIb9 or the amino-terminal portions of both GPIIbα
and GPIIIα.10 McMillan et al.11 developed an
immunobead assay to detect ITP antibodies reactive to
GPIIb/IIIa or GPIb/IX that has a minimum specificity of
84.4 percent, raising the possibility that the long-
awaited laboratory diagnostic assay for ITP may be
forthcoming.
Polymorphic FcγR macrophage receptors
In ITP, autoantibody-coated platelets are removed
from the circulation by Fcγ receptors on mononuclear
macrophages, principally in the spleen. Among the
three families of Fcγ receptors that have been
recognized (FcγRI, FcγRII, and FcγRIII), there is
considerable diversity of structure and function.12
FcγRI has a strong affinity for monomeric IgG. FcγRII
and FcγRIII bind IgG only when it presents in an
immune complex. FcγRII is polymorphic and two
codominant alleles have been described,FcγRIIA-H131
and FcγRIIA-R131.12 In one study, the distribution of
FcγRII receptors was skewed toward the FcγRIIA-R131
allotype, suggesting that Fc receptor polymorphisms
may have a role in the pathophysiology of ITP or may
be responsible for modulating the immune response.12
In another study, there was no significant difference in
the distribution of FcγRIIA genotypes between ITP
patients and controls, but there was a correlation
between FcγRIIIA genotypes and the response to
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treatment.13 ITP autoantibodies have been identified in
all IgG subclasses. The most prevalent IgG subclass
detected among ITP antibodies is IgG1 (77%),but IgG2,
IgG3, and IgG4 ITP antibodies have been identified.14
Further complicating the effort to identify a correlation
between diagnosis or prognosis for ITP and a specific
laboratory marker (i.e., antibody specificity, FcγR
genotype, or the IgG subclass) is the observation that
some patients with ITP appear to have oligoclonal
platelet antibodies, whereas other patients have
polyclonal antibodies.14
Selected Treatments for ITP
In many persons with ITP, particularly children,
thrombocytopenia resolves without specific treatment
after a benign course lasting only a few days to a few
weeks. Other persons may have sustained thrombocy-
topenia with life-threatening hemorrhages and a
treatment-resistant clinical course lasting several years.
For readers of Immunohematology with an interest in
reading more than selected aspects of the treatment for
ITP, I recommend the March 2002 issue of Blood
Reviews, which contains 21 articles focused primarily
on clinical management.6 The following brief
comments are intended to address selected aspects of
the treatment of ITP that have special relevance to
immunohematologists and blood bank serologists.
The goal of current treatments for ITP is to
decrease the synthesis of the platelet autoantibodies
and/or decrease the rate of splenic destruction of
autoantibody-coated platelets.
Splenectomy
The rationale for splenectomy in ITP is supported
by studies that show elimination of both the white
pulp (immune function) and red pulp (phagocytic
function) are beneficial.4 Following splenectomy in
ITP, antiplatelet antibodies decrease.15 This finding is
not unexpected, since cultured splenic cells isolated
from ITP patients synthesize IgG platelet antibodies.16
Also, splenectomy removes those mononuclear
macrophages most likely to be responsible for
destroying ITP autoantibody-coated platelets.
IVIG
A single infusion of a standard dose of IVIG (1
gram/kg) causes broad perturbations of both humoral
and cellular immune function.17 However, the
preponderance of evidence supports Imbach’s original
explanation that the principal mechanism of IVIG’s
beneficial effect in ITP is a consequence of
“overloading and blocking of the reticuloendothelial
system by IgG catabolism.”18 Fehr et al.19 showed that
increased platelet counts following infusions of IVIG in
four patients with ITP correlated with decreased
clearance of IgG-coated RBCs, providing experimental
evidence supporting Imbach’s hypothesis.
A single infusion of IVIG (1 gm/kg) is likely to be
highly effective (> 85%) for increasing the platelet
count by at least 30,000/µL in a previously untreated
child or adult with ITP. Typically, the beneficial effect
will last for 2 to 4 weeks, when a repeat infusion is
needed to sustain the beneficial effect. However, if
thrombocytopenia persists, the inconvenience of long
infusions (3 to 5 hours),higher cost compared to IV Rh
immune globulin (see below), and acute side effects
(headache, flulike symptoms) often cause patients and
physicians to consider alternative treatment programs.
Anti-D (IV Rh immune globulin)
In 1983, Salama et al.20 reported that microgram
doses of anti-D (IV Rh immune globulin, IV RhIG) in D+
patients with ITP increased platelet counts in ITP to
levels comparable to those reported after infusing gram
doses of IVIG. Whereas IVIG-induced Fcγ receptor
block results from random IgG molecules binding to
mononuclear macrophages’ Fcγ receptors, IV RhIG-
induced Fcγ receptor block in D+ patients leverages the
larger and more numerous anti-D-coated D+ RBCs to
compete with smaller and fewer autoantibody-coated
platelets for Fcγ receptor binding. Assuming a
representative platelet count of 10,000/µL and a normal
RBC count of 5,000,000/µL in a patient with ITP, the
competition of approximately 500 anti-D-coated D+
RBCs versus one autoantibody-coated platelet (500:1)
favors phagocytosis of the RBCs and “RES blockade” of
platelet sequestration and destruction.21 The efficacy of
IV RhIG for increasing platelet counts in ITP has been
confirmed by several studies (summarized in reference
22). In North America, treatment of patients with ITP
with IV RhIG is increasingly popular compared to IVIG,
because of the availability of an FDA-approved IV Rh
immune globulin (WinRho SDF, Nabi, Boca Raton, FL),
and its lower cost, ease of administration, and fewer
acute side effects.23, 24 WinRho is neither effective nor
FDA-approved for treatment of ITP in D– patients. D–
patients with ITP (approximately 15% of Caucasians are
D–) may be treated with IVIG. Rarely, recipients of a
standard dose have experienced acute intravascular
hemolysis,with hemoglobinemia and hemoglobinuria.25
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No specific factor has been identified that predicts an
acute hemolytic reaction,nor is there an explanation for
the variable clinical responses observed after treatment
with IV RhIG, raising the possibility that WinRho may
have a variable avidity for different Rh phenotypes,
reflecting the number of D antigen sites on the RBC
membrane (dosage effect).26 This hypothesis was
investigated using WinRho-coated RBCs of selected Rh
phenotypes in direct hemagglutination and monocyte
monolayer assays (MMAs), but neither serologic dosage
effect nor differentiating reactivity of MMAs for RBCs
with a double dose of D antigen was demonstrated.26
Readers are reminded that while WinRho is commonly
called “anti-D,” it is manufactured from pools of plasma
collected from alloimmunized D– persons and different
production lots may contain, in addition to anti-D,
variable concentrations of anti-E, -C, -G and/or other
alloantibodes.27 WhenWinRho is infused intravenously
to treat ITP in a D+ patient, the IV bolus (50–75 µg/kg)
is approximately 10 times the conventional
intramuscular dose used for Rh immunoprophylaxis in
D– women (300 µg, total dose). Therefore, serologic
testing shortly after an infusion may detect multiple
passively infused blood group alloantibodies, as well as
the expected positive DAT.27 The presence of anti-D in
the plasma of D+ ITP patients after an infusion of
WinRho often raises the question, “Should D+ or D–
RBCs be selected for transfusion, if required?” In this
author’s opinion, the decision should be based on the
immediate clinical priority. For example, if RBCs are
required to treat anemia secondary to metrorrhagia in a
woman with newly diagnosed ITP who remains
thrombocytopenic, I favor transfusing D+ RBCs to react
with any circulating WinRho and contribute to the
immediate goal of increasing the platelet count. In
contrast, if a patient is anemic, but no longer
thrombocytopenic after an infusion of WinRho, I favor




CA; and Biogen Idec, Inc., Cambridge, MA) is a
humanized IgG1/κ monoclonal anti-CD20 that is
indicated for the treatment of patients with relapsed or
refractory, low-grade or follicular, CD20-positive B-cell
non-Hodgkin lymphoma. Typically, an infusion of
rituximab is followed by a rapid decrease in B-
lymphocytes with less myelosuppression than usually
is observed with other immunosuppressive agents. As
a consequence, rituximab is used increasingly “off
label” to treat adults28 and children29 with chronic or
refractory ITP. Reports of sustained remissions in many
patients, together with the relatively selective B-cell
immunosuppression, suggest that rituximab is likely to
have an increasingly important role in the future
management of ITP.
Treating Helicobacter pylori infection
In 1998,Gasbarrini et al.30 reported that eradication
of Helicobacter pylori (H. pylori) in eight Italian adults
with ITP and H. pylori gastric infections resulted in
significantly increased platelet counts. This finding was
supported subsequently by studies of H.pylori–infected
persons with ITP in Italy and Japan.31–34 In contrast, in a
carefully controlled study of H. pylori–infected ITP
patients in NewYork, only one of 15 patients whose H.
pylori infection had been eradicated experienced an
increased platelet count, and that response was
transient.35 Similarly, in a study in Spain, no significant
improvements in platelet counts were observed in 56
patients with chronic ITP after eradication of H. pylori
infection.36 The discrepancy in treatment outcomes
remains unexplained and has resulted in divergent
recommendations concerning the role of screening for
H. pylori infection in patients with ITP. As one might
anticipate, the authors of the study in Spain concluded
that “there is insufficient evidence to include a search
for H. pylori in the initial work-up of ITP patients.”36
Responding to this opinion, the authors of one of the
studies in Italy wrote that“the data acquired to date still
prompt us to consider the investigation and eradication
of H.pylori in ITP patients as a simple, inexpensive tool
in early management of the chronic disease. Even
though the percentage of patients who are responsive
to eradication treatment will be small, it should be
mandatory [italics added] for the physicians to avoid
the toxicity and discomfort that accompany long-term
prednisone and other immunosuppressive treatments,
also spenectomy.”37 In an editorial reviewing these
diverse findings, McCrae concluded, “Should patients
with ITP be routinely screened for H. pylori? At this
point, probably not.”38
For immunohematologists, a more intriguing
question may be whether antibodies to H. pylori
crossreact with antigens on platelets, causing ITP-like
immune destruction. As one hypothesis to explain the
inconsistent association of ITP and H. pylori infection,
Michel et al.35 suggested that “the expression of various
Lewis (Le) antigens by H. pylori isolates, and the
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subsequent production of anti-Le antibodies, could play
a role in ITP pathogenesis since platelets may adsorb
Lewis antigens from the plasma.” In fact, there are
significant data to support this hypothesis, since Leb
functions as a receptor for H. pylori in the gastric
mucosa39–41 and Leb may be adsorbed from plasma by
platelet membranes.42 At the 1982 annual meeting of the
American Association of Blood Banks, McGinniss
reviewed the “ubiquitous nature of human blood group
antigens” that are shared between RBCs, bacteria,
viruses, and parasites.43 The relationship between Lewis
antigens, RBCs, gastric mucosa, platelets, and H. pylori
was not recognized at that time. However, the H.
pylori–ITP issue would appear to present yet one more
example of antigens that are shared among human blood
cells and the diverse microbial agents that infect us.
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